An analysis of 1408 patients treated in the AIEOP-BFM ALL 2000 trial showed IKZF1plus in 6% of patients, in whom it was associated with a 5-year EFS of 53%, compared to 79% in patients with IKZF1 deletion alone, and 87% in those without an IKZF1 deletion [52]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.